Case number 2017-1575
Teva Pharmaceuticals USA, Inc v. Sandoz Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | TEVA PHARMACEUTICALS USA, INC v. SANDOZ INC. [OPINION] [precedential] (0) |
| Nov 20, 2018 | 123 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [566652] [PBC] [Entered: 11/20/2018 10:54 AM] (1) |
| Oct 12, 2018 | 121 | OPINION filed for the court by Reyna, Circuit Judge; Bryson, Circuit Judge and Stoll, Circuit Judge. Precedential Opinion. [556564] [PBC] [Entered: 10/12/2018 09:42 AM] (32) |
| Oct 12, 2018 | 122 | JUDGMENT filed. AFFIRMED. Terminated on the merits after oral argument. COSTS: No Costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [556602] [PBC] [Entered: 10/12/2018 10:30 AM] (2) |
| May 1, 2018 | 120 | Submitted after ORAL ARGUMENT by John C. O'Quinn for Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., Yeda Research and Development Co., Ltd. and Teva Neuroscience, Inc. and Shannon Bloodworth and Deanne Maynard for Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Inc., Dr Reddy's Laboratories Ltd, Momenta Pharmaceuticals Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., Sandoz Inc., Synthon B.V., Synthon Pharmaceuticals, Inc., and Synthon S.r.o. Blansko Panel: Judge: Reyna , Judge: Bryson , Judge: Stoll. [518013] [JAB] [Entered: 05/01/2018 10:51 AM] (0) |
| Apr 27, 2018 | 119 | Entry of appearance for Seth W. Lloyd as of counsel for Appellees Momenta Pharmaceuticals Inc. and Sandoz Inc.. Service: 04/27/2018 by email. [517537] [17-1575] [Seth Lloyd] [Entered: 04/27/2018 06:41 PM] (2) |
| Apr 18, 2018 | 111 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:calendar response Docket No. [110], ERROR: Counsel for appellees Amneal Pharmaceuticals Company GmbH and Amneal Pharmaceuticals LLC submitted a response to the oral argument order "Designating Counsel for Mylan Pharmaceuticals Inc. and Sandoz Inc. will be arguing on behalf of all appellees to argue". This is not an acceptable response. Counsel must indicate which attorney will argue for the parties and for how much time. CORRECTION: Please promptly submit a corrected response. [514668] [JAB] [Entered: 04/18/2018 07:53 AM] (0) |
| Apr 18, 2018 | 112 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:calendar response Docket No. [108], calendar response Docket No. [109], ERROR: Counsel on behalf of appellees Dr Reddy's Laboratories Inc., Dr Reddy's Laboratories Ltd., Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko submitted responses to the oral argument order designating multiple arguing attorneys. If multiple attorneys are arguing, SEPARATE responses must be filed indicating the amount of time each attorney is planning to argue. CORRECTION: Please promptly submit separate corrected responses (one for each arguing attorney). [514671] [JAB] [Entered: 04/18/2018 08:29 AM] (0) |
| Apr 18, 2018 | 113 | CORRECTEDResponse to oral argument order from the Appellees Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Designating Shannon M. Bloodworth to argue.. Designating 10 minutes for argument. Reserving 0 minutes for rebuttal. [17-1575] [Edward Figg] [Entered: 04/18/2018 09:00 AM] (0) |
| Apr 18, 2018 | 114 | CORRECTEDResponse to oral argument order from the Appellees Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Designating Deanne E. Maynard to argue.. Designating 5 minutes for argument. Reserving 0 minutes for rebuttal. [17-1575] [Edward Figg] [Entered: 04/18/2018 09:02 AM] (0) |
| Apr 18, 2018 | 115 | CORRECTEDResponse to oral argument order from the Appellees Dr Reddy's Laboratories Inc. and Dr Reddy's Laboratories Ltd. Designating Shannon M. Bloodworth to argue.. Designating 10 minutes for argument. Reserving 0 minutes for rebuttal. [17-1575] [Louis Weinstein] [Entered: 04/18/2018 09:32 AM] (0) |
| Apr 18, 2018 | 116 | CORRECTEDResponse to oral argument order from the Appellees Dr Reddy's Laboratories Inc. and Dr Reddy's Laboratories Ltd. Designating Deanne E. Maynard to argue.. Designating 5 minutes for argument. Reserving 0 minutes for rebuttal. [17-1575] [Louis Weinstein] [Entered: 04/18/2018 09:34 AM] (0) |
| Apr 18, 2018 | 117 | CORRECTED Response to oral argument order from the Appellees Amneal Pharmaceuticals Company GmbH and Amneal Pharmaceuticals LLC. Designating Shannon M. Bloodworth to argue.. Designating 10 minutes for argument. Reserving 0 minutes for rebuttal. [17-1575] [Anthony Fitzpatrick] [Entered: 04/18/2018 01:20 PM] (0) |
| Apr 18, 2018 | 118 | CORRECTED Response to oral argument order from the Appellees Amneal Pharmaceuticals Company GmbH and Amneal Pharmaceuticals LLC. Designating Deanne E. Maynard to argue.. Designating 5 minutes for argument. Reserving 0 minutes for rebuttal. [17-1575] [Anthony Fitzpatrick] [Entered: 04/18/2018 01:23 PM] (0) |
| Apr 17, 2018 | 104 | Notice to counsel for Appellees Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Inc., Dr Reddy's Laboratories Ltd, Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko: The record of this case indicates that the responses to the oral argument order have not been filed. The responses were due on or before 04/16/2018. Counsel should promptly docket the Response to Oral Argument Order event and designate which attorneys will present argument for the parties. Service as of this date by the Clerk of Court. [514079] [JAB] [Entered: 04/17/2018 11:59 AM] (0) |
| Apr 17, 2018 | 105 | Response to oral argument order from the Appellees Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Designating Shannon M. Bloodworth and Deanne E. Maynard to argue.. Designating 15 minutes for argument. Reserving 0 minutes for rebuttal. [17-1575] [Edward Figg] [Entered: 04/17/2018 01:27 PM] (0) |
| Apr 17, 2018 | 106 | Response to oral argument order from the Appellees Dr Reddy's Laboratories Inc. and Dr Reddy's Laboratories Ltd. Designating Shannon M. Bloodworth and Deanne E. Maynard to argue.. Designating 15 minutes for argument. Reserving 0 minutes for rebuttal. [17-1575] [Louis Weinstein] [Entered: 04/17/2018 01:40 PM] (0) |
| Apr 17, 2018 | 107 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:calendar response Docket No. [105], calendar response Docket No. [106], ERROR: Counsel on behalf of appellees Dr Reddy's Laboratories Inc., Dr Reddy's Laboratories Ltd., Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko submitted responses to the oral argument order designating multiple arguing attorneys. If multiple attorneys are arguing, separate responses must be filed indicating the amount of time each attorney is planning to argue. CORRECTION: Please promptly submit corrected responses. [514164] [JAB] [Entered: 04/17/2018 02:36 PM] (0) |
| Apr 17, 2018 | 108 | CORRECTEDResponse to oral argument order from the Appellees Dr Reddy's Laboratories Inc. and Dr Reddy's Laboratories Ltd. Designating Shannon M. Bloodworth 10 minutes and Deanne E. Maynard 5 minutes to argue.. Designating 15 minutes for argument. Reserving 0 minutes for rebuttal. [17-1575] [Louis Weinstein] [Entered: 04/17/2018 02:43 PM] (0) |
| Apr 17, 2018 | 109 | CORRECTEDResponse to oral argument order from the Appellees Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Designating Shannon M. Bloodworth 10 minutes and Deanne E. Maynard 5 minutes to argue.. Designating 15 minutes for argument. Reserving 0 minutes for rebuttal. [17-1575] [Edward Figg] [Entered: 04/17/2018 03:12 PM] (0) |
| Apr 17, 2018 | 110 | Response to oral argument order from the Appellees Amneal Pharmaceuticals Company GmbH and Amneal Pharmaceuticals LLC. Designating Counsel for Mylan Pharmaceuticals Inc. and Sandoz Inc. will be arguing on behalf of all appellees to argue. [17-1575] [Anthony Fitzpatrick] [Entered: 04/17/2018 03:49 PM] (0) |
| Apr 16, 2018 | 100 | Response to oral argument order from the Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Designating Shannon M. Bloodworth to argue.. Designating 10 minutes for argument. [17-1575] [Dan Bagatell] [Entered: 04/16/2018 03:48 PM] (0) |
| Apr 16, 2018 | 101 | Entry of appearance for Deanne E. Maynard as of counsel for Appellees Sandoz Inc. and Momenta Pharmaceuticals Inc.. Service: 04/16/2018 by email. [513853] [17-1575] [Deanne Maynard] [Entered: 04/16/2018 04:19 PM] (2) |
| Apr 16, 2018 | 102 | Response to oral argument order from the Appellees Sandoz Inc. and Momenta Pharmaceuticals Inc.. Designating Deanne E. Maynard to argue.. Designating 5 minutes for argument. [17-1575] [Deanne Maynard] [Entered: 04/16/2018 04:20 PM] (0) |
| Apr 16, 2018 | 103 | Response to oral argument order from the Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Designating John O'Quinn to argue.. Designating 11 minutes for argument. Reserving 4 minutes for rebuttal. [17-1575] [John O'Quinn] [Entered: 04/16/2018 05:52 PM] (0) |
| Apr 12, 2018 | 98 | MOTION of Appellees Dr Reddy's Laboratories Inc. and Dr Reddy's Laboratories Ltd to withdraw counsel Alfred Hank Heckel. Any response is due within 10 days of service. [Consent: unopposed]. Service: 04/12/2018 by email. [512870] [17-1575] [Louis Weinstein] [Entered: 04/12/2018 01:15 PM] (6) |
| Apr 12, 2018 | 99 | **TEXT ONLY** ORDER granting motion to withdraw attorney Alfred Hank Heckel [98] filed by Appellees Dr Reddy's Laboratories Ltd and Dr Reddy's Laboratories Inc. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [512884] [JAB] [Entered: 04/12/2018 01:47 PM] (0) |
| Mar 28, 2018 | 97 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [34], ERROR: The entry of appearance for Alfred Henry Heckel includes a firm name and contact information that does not match counsel's ECF filer information. CORRECTION: Counsel must promptly update his contact information with the PACER Service Center. [508673] [JAB] [Entered: 03/28/2018 01:09 PM] (0) |
| Mar 22, 2018 | 96 | NOTICE OF CALENDARING. Panel: 1805G. Case scheduled May 01, 2018 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 203. Response to oral argument order due: 04/16/2018. Arguing counsel is required to check-in with the Clerk's Office, 4th Floor, Room 401, between 8:30 a.m. and 9:30 a.m. on the day of argument. Please review the Oral Argument Order. [507294] [JAB] [Entered: 03/22/2018 04:32 PM] (0) |
| Mar 21, 2018 | 95 | Notice from Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. regarding conflicts with oral argument (Unavailable May 4, in addition to conflicts identified in previous letters). Service: 03/21/2018 by email, US mail. [506966] [17-1575] [John O'Quinn] [Entered: 03/21/2018 05:05 PM] (3) |
| Mar 6, 2018 | 94 | Notice from Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. regarding conflicts with oral argument ([update from 1/29/2018 ltr]: request not to schedule argument May 2-3, June 5, June 7, or during same session as nos. 17-1094, 17-1744, 17-2490, 17-2173, or 17-2106). Service: 03/06/2018 by email, US mail. [502945] [John O'Quinn] [Entered: 03/06/2018 04:32 PM] (2) |
| Jan 29, 2018 | 93 | Notice from Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. regarding conflicts with oral argument ([updated from 12/6/2017 ltr] request not to schedule argument April 2-9, or during same session as nos. 17-1094, 17-1784, 17-1744, or 17-2173). Service: 01/29/2018 by email, US mail. [493254] [John O'Quinn] [Entered: 01/29/2018 10:18 AM] (2) |
| Dec 6, 2017 | 92 | Notice from Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. regarding conflicts with oral argument ([updated from 11/14 ltr]: request not to schedule argument in February 2018, Mar. 8, April 5 or 9, or during the same argument session as nos. 17-1094, 17-1131, 17-1784, 17-1525, 17-1798, or 17-2173). Service: 12/06/2017 by email, US mail. [480590] [John O'Quinn] [Entered: 12/06/2017 12:56 PM] (3) |
| Nov 14, 2017 | 91 | Notice from Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. regarding conflicts with oral argument ([updated from 10/17/17 ltr]: request not to schedule argument January 11-12, February 7-9, March 8, April 5 or during same week as No. 17-1094, 17-1131, 17-1525, 17-1784, or 17-1798). Service: 11/14/2017 by email, US mail. [475517] [John O'Quinn] [Entered: 11/14/2017 05:23 PM] (2) |
| Oct 17, 2017 | 88 | 6 paper copies of the Joint Appendix (Vols. I-III) [84] received from Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. [468550] [CW] [Entered: 10/17/2017 04:05 PM] (0) |
| Oct 17, 2017 | 89 | Notice from Appellees Momenta Pharmaceuticals Inc. and Sandoz Inc. regarding conflicts with oral argument (November 6-9, 2017). Service: 10/17/2017 by email. [468611] [Erin Forbes] [Entered: 10/17/2017 05:40 PM] (2) |
| Oct 17, 2017 | 90 | Notice from Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. regarding conflicts with oral argument (December 7-8, January 11-12, February 7-9, March 8, April 5; request not to schedule argument same week as nos. 15-2021, 17-1094, 17-1131, or 17-1798). Service: 10/17/2017 by email, US mail. [468632] [John O'Quinn] [Entered: 10/17/2017 08:10 PM] (2) |
| Oct 10, 2017 | 85 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks, or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 10/17/2017. [466403] [JB] [Entered: 10/10/2017 10:27 AM] (0) |
| Oct 10, 2017 | 86 | 6 paper copies of the Reply Brief [77] received from Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc. [466455] [CW] [Entered: 10/10/2017 11:38 AM] (0) |
| Oct 10, 2017 | 87 | 6 paper copies of the Opening Brief [78] received from Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. [466458] [CW] [Entered: 10/10/2017 11:40 AM] (0) |
| Oct 6, 2017 | 79 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Momenta Pharmaceuticals Inc. and Sandoz Inc.. Service: 10/06/2017 by email. [466260] [Erin Forbes] [Entered: 10/06/2017 05:06 PM] (3) |
| Oct 6, 2017 | 80 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Service: 10/06/2017 by email, US mail. [466263] [Edward Figg] [Entered: 10/06/2017 05:11 PM] (5) |
| Oct 6, 2017 | 81 | TENDERED from Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Title: JOINT APPENDIX. Service: 10/06/2017 by email, US mail. [466280] [John O'Quinn] [Entered: 10/06/2017 09:54 PM] (1453) |
| Oct 6, 2017 | 82 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Service: 10/06/2017 by email, US mail. [466281] [John O'Quinn] [Entered: 10/06/2017 09:58 PM] (3) |
| Oct 6, 2017 | 83 | Statement of Compliance with Fed. Cir. R. 33 for Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., Yeda Research and Development Co., Ltd. and Appellees Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Inc., Dr Reddy's Laboratories Ltd, Momenta Pharmaceuticals Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., Sandoz Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Service: 10/06/2017 by email, US mail. [466282] [John O'Quinn] [Entered: 10/06/2017 10:04 PM] (3) |
| Oct 6, 2017 | 84 | APPENDIX FILED for Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. [81]. Number of Pages: 1453. Service: 10/06/2017 by email. The paper copies of the brief should be received by the court on or before 10/17/2017. [466319] [JB] [Entered: 10/10/2017 08:39 AM] (1453) |
| Sep 29, 2017 | 74 | TENDERED from Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Title: REPLY BRIEF. Service: 09/29/2017 by email, US mail. [464529] [John O'Quinn] [Entered: 09/29/2017 08:39 PM] (46) |
| Sep 29, 2017 | 75 | Notice of Correction to the Brief Doc No. [62] for Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Service: 09/29/2017 by email, US mail. [464530] [John O'Quinn] [Entered: 09/29/2017 08:40 PM] (4) |
| Sep 29, 2017 | 76 | TENDERED from Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Title: CORRECTED OPENING BRIEF. Service: 09/29/2017 by email, US mail. [464531] [John O'Quinn] [Entered: 09/29/2017 08:42 PM] (214) |
| Sep 29, 2017 | 77 | REPLY BRIEF FILED for Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. [74]. Number of Pages: 35. Service: 09/29/2017 by email. The paper copies of the brief should be received by the court on or before 10/10/2017. Appendix is due 10/06/2017. [464811] [JB] [Entered: 10/02/2017 02:46 PM] (46) |
| Sep 29, 2017 | 78 | CORRECTED BRIEF FILED for Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. [76]. Number of Pages: 77. Service: 09/29/2017 by email. The paper copies of the brief should be received by the court on or before 10/10/2017. [464844] [JB] [Entered: 10/02/2017 03:45 PM] (214) |
| Aug 25, 2017 | 72 | 6 paper copies of the Opening Response Brief [70] received from Appellees Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Inc., Dr Reddy's Laboratories Ltd, Momenta Pharmaceuticals Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., Sandoz Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. [456680] [CW] [Entered: 08/25/2017 12:34 PM] (0) |
| Aug 25, 2017 | 73 | **TEXT ONLY** ORDER granting motion to extend time to file reply brief [71] filed by Appellants Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., Yeda Research and Development Co., Ltd. and Teva Neuroscience, Inc. Appellants reply brief is due 09/29/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [456823] [JB] [Entered: 08/25/2017 04:06 PM] (0) |
| Aug 24, 2017 | 71 | MOTION of Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. to extend the time to 09/29/2017 to file the reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 08/24/2017 by email, US mail. [456511] [John O'Quinn] [Entered: 08/24/2017 07:04 PM] (9) |
| Aug 18, 2017 | 69 | TENDERED from Appellees Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Inc., Dr Reddy's Laboratories Ltd, Momenta Pharmaceuticals Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., Sandoz Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Title: RESPONSE BRIEF. Service: 08/18/2017 by email, US mail. [455200] [Dan Bagatell] [Entered: 08/18/2017 04:21 PM] (82) |
| Aug 18, 2017 | 70 | BRIEF FILED for Appellees Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Inc., Dr Reddy's Laboratories Ltd, Momenta Pharmaceuticals Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., Sandoz Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko [69]. Number of Pages: 64. Service: 08/18/2017 by email. The paper copies of the brief should be received by the court on or before 08/29/2017. Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. reply brief is due 09/01/2017. [455653] [JB] [Entered: 08/22/2017 09:26 AM] (82) |
| Jul 7, 2017 | 66 | **TEXT ONLY** ORDER granting motion to extend time to file appellee/respondent/cross-appellant principal brief [65] filed by Appellees Mylan Pharmaceuticals Inc., Mylan Inc., Pfizer Inc., Synthon Pharmaceuticals, Inc., Momenta Pharmaceuticals Inc., Sandoz Inc., Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Ltd, Dr Reddy's Laboratories Inc., Synthon B.V., Synthon S.r.o. Blansko and Amneal Pharmaceuticals Company GmbH. Appellees' brief is due on 08/18/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [444744] [JB] [Entered: 07/07/2017 10:05 AM] (0) |
| Jul 7, 2017 | 67 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: motion to extend time to file appellee/respondent/cross-appellant principal brief [65], ERROR: Attorney Christina J. McCullough, listed on the motion, has not filed an entry of appearance in this case. CORRECTION: Attorney Christina J. McCullough should file an entry of appearance in this case as soon as possible. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [444748] [JB] [Entered: 07/07/2017 10:15 AM] (0) |
| Jul 7, 2017 | 68 | Entry of appearance for Christina J. McCullough as of counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 07/07/2017 by email, US mail. [444820] [Christina McCullough] [Entered: 07/07/2017 12:24 PM] (2) |
| Jul 6, 2017 | 65 | MOTION of Appellees Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Inc., Dr Reddy's Laboratories Ltd, Momenta Pharmaceuticals Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., Sandoz Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko to extend the time to 08/18/2017 at 11:59 pm to file the appellee/respondent/cross-appellant's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 07/06/2017 by email, US mail. [444664] [Dan Bagatell] [Entered: 07/06/2017 08:24 PM] (14) |
| Jun 13, 2017 | 64 | 6 paper copies of the Opening Brief [63] received from Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. [438859] [JCP] [Entered: 06/13/2017 02:18 PM] (0) |
| Jun 6, 2017 | 62 | TENDERED from Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Title: OPENING BRIEF. Service: 06/06/2017 by email, US mail. [436908] This brief has been corrected. See Doc No. [78] [John O'Quinn] [Entered: 06/06/2017 07:53 PM] (0) |
| Jun 6, 2017 | 63 | BRIEF FILED for Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. [62]. Number of Pages: 77. Service: 06/06/2017 by email. The paper copies of the brief should be received by the court on or before 06/14/2017. Appellees Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Inc., Dr Reddy's Laboratories Ltd, Momenta Pharmaceuticals Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., Sandoz Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko brief is due 07/17/2017. [437166] This brief has been corrected. See Doc No.[78] [JB] [Entered: 06/07/2017 02:14 PM] (0) |
| May 25, 2017 | 60 | Entry of appearance for Louis H. Weinstein as of counsel for Appellees Dr Reddy's Laboratories Inc. and Dr Reddy's Laboratories Ltd. Service: 05/25/2017 by email. [434232] [Louis Weinstein] [Entered: 05/25/2017 04:12 PM] (2) |
| May 25, 2017 | 61 | Certificate of Interest for the Appellees Dr Reddy's Laboratories Inc. and Dr Reddy's Laboratories Ltd. Service: 05/25/2017 by email. [434235] [Louis Weinstein] [Entered: 05/25/2017 04:15 PM] (3) |
| May 15, 2017 | 59 | Entry of appearance for Leslie M. Schmidt as of counsel for Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Service: 05/15/2017 by email, US mail. [431594] [Leslie Schmidt] [Entered: 05/15/2017 05:45 PM] (2) |
| Apr 18, 2017 | 58 | Amended Certificate of Interest for the Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 04/18/2017 by email, US mail. [425213] [Shannon Bloodworth] [Entered: 04/18/2017 03:25 PM] (3) |
| Mar 27, 2017 | 57 | **TEXT ONLY** ORDER granting motion to extend time to file appellant/petitioner principal brief [56] filed by Appellants Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., Yeda Research and Development Co., Ltd. and Teva Neuroscience, Inc. Brief is due on 06/06/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [419124] [JB] [Entered: 03/27/2017 01:24 PM] (0) |
| Mar 24, 2017 | 56 | MOTION of Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd. to extend the time to 06/06/2017 to file the appellant/petitioner's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 03/24/2017 by email, US mail. [418882] [William Jay] [Entered: 03/24/2017 04:31 PM] (8) |
| Mar 22, 2017 | 55 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [417699] [JB] [Entered: 03/22/2017 08:32 AM] (0) |
| Mar 15, 2017 | 54 | Entry of appearance for William G. James as of counsel for Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Service: 03/15/2017 by email, US mail. [415939] [William Jay] [Entered: 03/15/2017 07:31 PM] (2) |
| Mar 2, 2017 | 52 | Entry of appearance for Erin M. Forbes as of counsel for Appellees Momenta Pharmaceuticals Inc. and Sandoz Inc.. Service: 03/02/2017 by email. [412101] [Erin Forbes] [Entered: 03/02/2017 04:17 PM] (2) |
| Mar 2, 2017 | 53 | Entry of appearance for Christopher Patrick Galligan as of counsel for Appellees Momenta Pharmaceuticals Inc. and Sandoz Inc.. Service: 03/02/2017 by email. [412105] [Christopher Galligan] [Entered: 03/02/2017 04:21 PM] (2) |
| Mar 1, 2017 | 50 | ORDER filed. Appeal Nos. 2017-1575 and 2017-1594, -1595, -1596 shall be considered companion cases and assigned to the same merits panel. Service: 03/01/2017 by clerk. [411686] [17-1575, 17-1594] [LMS] [Entered: 03/01/2017 02:32 PM] (2) |
| Mar 1, 2017 | 51 | Note to file: 17-1594, 17-1595, 17-1596 (COMPANION started 03/01/2017) with 17-1575. These cases shall be considered companion cases and assigned to the same merits panel for oral argument. [411712] [JB] [Entered: 03/01/2017 03:19 PM] (0) |
| Feb 27, 2017 | 49 | Clerk's Note to the File: Parties are reminded that the official short caption for this case is Teva Pharmaceuticals USA, Inc., et al. v. Sandoz Inc., et al.. Any further filings should comply with the official short caption. [410665] [CMP] [Entered: 02/27/2017 08:58 AM] (0) |
| Feb 22, 2017 | 37 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: The entries of appearance for Appelles Amneal Pharmaceuticals Company GmbH and Amneal Pharmaceuticals LLC (Nos. [2], [7], [4], and [3]) were submitted as editable forms. CORRECTION: Please ensure future filings are submitted in a non-editable format. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [409476] [CMP] [Entered: 02/22/2017 08:29 AM] (0) |
| Feb 22, 2017 | 38 | NOTICE OF DEFICIENCY: The Entries of Appearance for WIlliam M. Jay, Elizabeth J. Holland, and Daryl L. Wiesen (Nos. [27], [35], and [36]) filed by Appellants must list all parties being represented on the form and in the docket entry; "Et al." is not sufficient and therefore these forms cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiencies. At the discretion of the court, the corrected documents may be accepted for filing if received before midnight (EST) on the date of this notice. [409519] [CMP] [Entered: 02/22/2017 09:47 AM] (0) |
| Feb 22, 2017 | 39 | Corrected Entry of appearance for John C. O'Quinn as principal counsel for Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Service: 02/22/2017 by email. [409530] [John O'Quinn] [Entered: 02/22/2017 10:05 AM] (2) |
| Feb 22, 2017 | 40 | Corrected Entry of appearance for Sharon L. Davis as of counsel for Appellees Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Service: 02/22/2017 by email, US mail. [409549] [Sharon Davis] [Entered: 02/22/2017 10:28 AM] (2) |
| Feb 22, 2017 | 41 | Corrected Entry of appearance for Seth E. Cockrum as of counsel for Appellees Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Service: 02/22/2017 by email. [409552] [Seth Cockrum] [Entered: 02/22/2017 10:30 AM] (2) |
| Feb 22, 2017 | 42 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Alfred Henry Heckel's entry of appearance ([34]) includes a firm name and contact information on the form that does not match the information associated with Counsel's record. CORRECTION: Counsel should promptly update his contact information with the PACER Service Center and register for this court's CM/ECF system. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [409553] [CMP] [Entered: 02/22/2017 10:30 AM] (0) |
| Feb 22, 2017 | 43 | Entry of appearance for Ellen T. Lowenthal as of counsel for Appellees Dr Reddy's Laboratories Inc. and Dr Reddy's Laboratories Ltd. Service: 02/22/2017 by email. [409720] [Ellen Lowenthal] [Entered: 02/22/2017 02:50 PM] (2) |
| Feb 22, 2017 | 44 | Corrected Entry of appearance for William M. Jay as of counsel for Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Service: 02/22/2017 by email. [409773] [William Jay] [Entered: 02/22/2017 04:16 PM] (2) |
| Feb 22, 2017 | 45 | Corrected Entry of appearance for Elizabeth J. Holland as of counsel for Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Service: 02/22/2017 by email. [409782] [Elizabeth Holland] [Entered: 02/22/2017 04:23 PM] (2) |
| Feb 22, 2017 | 46 | Corrected Entry of appearance for Daryl L. Wiesen as of counsel for Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Service: 02/22/2017 by email. [409789] [Daryl Wiesen] [Entered: 02/22/2017 04:34 PM] (2) |
| Feb 22, 2017 | 47 | Entry of appearance for Brandon M. White as of counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 02/22/2017 by email. [409800] [Robert Swanson] [Entered: 02/22/2017 05:13 PM] (2) |
| Feb 22, 2017 | 48 | Entry of appearance for Robert D. Swanson as of counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 02/22/2017 by email. [409801] [Robert Swanson] [Entered: 02/22/2017 05:15 PM] (2) |
| Feb 21, 2017 | 2 | Entry of appearance for Anthony J. Fitzpatrick as principal counsel for Appellees Amneal Pharmaceuticals Company GmbH and Amneal Pharmaceuticals LLC. Service: 02/21/2017 by email. [409326] [Anthony Fitzpatrick] [Entered: 02/21/2017 04:21 PM] (1) |
| Feb 21, 2017 | 3 | Entry of appearance for Christopher S. Kroon as of counsel for Appellees Amneal Pharmaceuticals Company GmbH and Amneal Pharmaceuticals LLC. Service: 02/21/2017 by email. [409330] [Anthony Fitzpatrick] [Entered: 02/21/2017 04:22 PM] (1) |
| Feb 21, 2017 | 4 | Entry of appearance for Patrick C. Gallagher as of counsel for Appellees Amneal Pharmaceuticals Company GmbH and Amneal Pharmaceuticals LLC. Service: 02/21/2017 by email. [409334] [Anthony Fitzpatrick] [Entered: 02/21/2017 04:24 PM] (1) |
| Feb 21, 2017 | 5 | Certificate of Interest for the Appellees Amneal Pharmaceuticals Company GmbH and Amneal Pharmaceuticals LLC. Service: 02/21/2017 by email. [409342] [Anthony Fitzpatrick] [Entered: 02/21/2017 04:26 PM] (1) |
| Feb 21, 2017 | 6 | Docketing Statement for the Appellees Amneal Pharmaceuticals Company GmbH and Amneal Pharmaceuticals LLC. Service: 02/21/2017 by email. [409346] [Anthony Fitzpatrick] [Entered: 02/21/2017 04:28 PM] (4) |
| Feb 21, 2017 | 7 | Entry of appearance for Vincent L. Capuano as of counsel for Appellees Amneal Pharmaceuticals Company GmbH and Amneal Pharmaceuticals LLC. Service: 02/21/2017 by email. [409351] [Vincent Capuano] [Entered: 02/21/2017 04:32 PM] (1) |
| Feb 21, 2017 | 8 | Entry of appearance for Edward Anthony Figg as principal counsel for Appellees Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Service: 02/21/2017 by email. [409365] [Edward Figg] [Entered: 02/21/2017 05:29 PM] (2) |
| Feb 21, 2017 | 9 | Certificate of Interest for the Appellees Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Service: 02/21/2017 by email. [409367] [Edward Figg] [Entered: 02/21/2017 05:32 PM] (3) |
| Feb 21, 2017 | 10 | Docketing Statement for the Appellees Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Service: 02/21/2017 by email. [409368] [Edward Figg] [Entered: 02/21/2017 05:33 PM] (3) |
| Feb 21, 2017 | 11 | Entry of appearance for Sharon L. Davis as of counsel for Appellees Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Service: 02/21/2017 by email. [409371] [Sharon Davis] [Entered: 02/21/2017 05:38 PM] (2) |
| Feb 21, 2017 | 12 | Entry of appearance for Seth E. Cockrum as of counsel for Appellees Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Service: 02/21/2017 by email. [409372] [Seth Cockrum] [Entered: 02/21/2017 05:40 PM] (2) |
| Feb 21, 2017 | 13 | Entry of appearance for Rachel Pernic Waldron as of counsel for Appellees Momenta Pharmaceuticals Inc. and Sandoz Inc.. Service: 02/21/2017 by email. [409373] [Rachel Waldron] [Entered: 02/21/2017 05:42 PM] (2) |
| Feb 21, 2017 | 14 | Entry of appearance for Brett A. Postal as of counsel for Appellees Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Service: 02/21/2017 by email. [409374] [Brett Postal] [Entered: 02/21/2017 05:42 PM] (2) |
| Feb 21, 2017 | 15 | Entry of appearance for Jennifer P. Nock as of counsel for Appellees Pfizer Inc., Synthon B.V., Synthon Pharmaceuticals, Inc. and Synthon S.r.o. Blansko. Service: 02/21/2017 by email. [409375] [Jennifer Nock] [Entered: 02/21/2017 05:44 PM] (2) |
| Feb 21, 2017 | 16 | Entry of appearance for William A. Rakoczy as principal counsel for Appellees Momenta Pharmaceuticals Inc. and Sandoz Inc.. Service: 02/21/2017 by email. [409376] [William Rakoczy] [Entered: 02/21/2017 05:47 PM] (2) |
| Feb 21, 2017 | 17 | Entry of appearance for Deanne M. Mazzochi as of counsel for Appellees Momenta Pharmaceuticals Inc. and Sandoz Inc.. Service: 02/21/2017 by email. [409380] [Deanne Mazzochi] [Entered: 02/21/2017 05:52 PM] (2) |
| Feb 21, 2017 | 18 | Entry of appearance for Shannon M. Bloodworth as principal counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 02/21/2017 by email. [409382] [Shannon Bloodworth] [Entered: 02/21/2017 05:55 PM] (2) |
| Feb 21, 2017 | 19 | Entry of appearance for Matthew V. Anderson as of counsel for Appellees Momenta Pharmaceuticals Inc. and Sandoz Inc.. Service: 02/21/2017 by email. [409384] [Matthew Anderson] [Entered: 02/21/2017 05:55 PM] (2) |
| Feb 21, 2017 | 20 | Certificate of Interest for the Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 02/21/2017 by email. [409386] [Shannon Bloodworth] [Entered: 02/21/2017 05:56 PM] (3) |
| Feb 21, 2017 | 21 | Docketing Statement for the Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 02/21/2017 by email. [409387] [Shannon Bloodworth] [Entered: 02/21/2017 05:58 PM] (4) |
| Feb 21, 2017 | 22 | Entry of appearance for Thomas H. Ehrich as of counsel for Appellees Momenta Pharmaceuticals Inc. and Sandoz Inc.. Service: 02/21/2017 by email. [409388] [Thomas Ehrich] [Entered: 02/21/2017 05:58 PM] (2) |
| Feb 21, 2017 | 23 | Docketing Statement for the Appellees Momenta Pharmaceuticals Inc. and Sandoz Inc.. Service: 02/21/2017 by email. [409392] [Rachel Waldron] [Entered: 02/21/2017 06:02 PM] (4) |
| Feb 21, 2017 | 24 | Certificate of Interest for the Appellees Momenta Pharmaceuticals Inc. and Sandoz Inc.. Service: 02/21/2017 by email. [409398] [Rachel Waldron] [Entered: 02/21/2017 06:08 PM] (3) |
| Feb 21, 2017 | 25 | Entry of appearance for Dan L. Bagatell as of counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 02/21/2017 by email. [409399] [Dan Bagatell] [Entered: 02/21/2017 06:08 PM] (2) |
| Feb 21, 2017 | 26 | Entry of appearance for David L. Anstaett as of counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 02/21/2017 by email. [409400] [Dan Bagatell] [Entered: 02/21/2017 06:10 PM] (2) |
| Feb 21, 2017 | 27 | Entry of appearance for William M. Jay as of counsel for Appellant Teva Pharmaceuticals USA, Inc.. Service: 02/21/2017 by email. [409413] [William Jay] [Entered: 02/21/2017 07:12 PM] (0) |
| Feb 21, 2017 | 28 | Certificate of Interest for Appellants Teva Pharmaceuticals USA, Inc., Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., and Yeda Research and Development Cp., Ltd. Service: 02/21/2017 by email. [409417]--[Edited 02/27/2017 by clerk to add party filers] [William Jay] [Entered: 02/21/2017 07:27 PM] (4) |
| Feb 21, 2017 | 29 | Entry of appearance for John C. O'Quinn as principal counsel for Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Service: 02/21/2017 by email. [409418] [John O'Quinn] [Entered: 02/21/2017 07:36 PM] (1) |
| Feb 21, 2017 | 30 | Docketing Statement for the Appellants Teva Neuroscience, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Yeda Research and Development Co., Ltd.. Service: 02/21/2017 by email. [409419] [William Jay] [Entered: 02/21/2017 07:37 PM] (5) |
| Feb 21, 2017 | 31 | Entry of appearance for Frank D. Rodriguez as principal counsel for Appellees Dr Reddy's Laboratories Inc. and Dr Reddy's Laboratories Ltd. Service: 02/21/2017 by email. [409420] [Frank Rodriguez] [Entered: 02/21/2017 07:39 PM] (2) |
| Feb 21, 2017 | 32 | Certificate of Interest for the Appellees Dr Reddy's Laboratories Inc. and Dr Reddy's Laboratories Ltd. Service: 02/21/2017 by email. [409421] [Frank Rodriguez] [Entered: 02/21/2017 07:40 PM] (3) |
| Feb 21, 2017 | 33 | Docketing Statement for the Appellees Dr Reddy's Laboratories Inc. and Dr Reddy's Laboratories Ltd. Service: 02/21/2017 by email. [409422] [Frank Rodriguez] [Entered: 02/21/2017 07:40 PM] (5) |
| Feb 21, 2017 | 34 | Entry of appearance for Alfred Henry Heckel as of counsel for Appellees Dr Reddy's Laboratories Inc. and Dr Reddy's Laboratories Ltd. Service: 02/21/2017 by email. [409423] [Frank Rodriguez] [Entered: 02/21/2017 07:42 PM] (2) |
| Feb 21, 2017 | 35 | Entry of appearance for Elizabeth J. Holland as of counsel for Appellant Teva Pharmaceuticals USA, Inc.. Service: 02/21/2017 by email. [409425] [Elizabeth Holland] [Entered: 02/21/2017 07:50 PM] (0) |
| Feb 21, 2017 | 36 | Entry of appearance for Daryl L. Wiesen as of counsel for Appellant Teva Pharmaceuticals USA, Inc.. Service: 02/21/2017 by email. [409427] [Daryl Wiesen] [Entered: 02/21/2017 07:58 PM] (0) |
| Feb 6, 2017 | 1 | Appeal docketed. Received: 02/03/2017. [404827]Entry of Appearance due 02/21/2017. Certificate of Interest is due on 02/21/2017. Docketing Statement due 02/21/2017. Appellant/Petitioner's brief is due 04/07/2017. [JB] [Entered: 02/06/2017 11:35 AM] (127) |
